Market Cap 696.85M
Revenue (ttm) 179.28M
Net Income (ttm) 17.49M
EPS (ttm) N/A
PE Ratio 7.27
Forward PE 9.22
Profit Margin 9.76%
Debt to Equity Ratio 0.46
Volume 846,400
Avg Vol 520,500
Day's Range N/A - N/A
Shares Out 17.94M
Stochastic %K 18%
Beta 1.21
Analysts Sell
Price Target $36.33

Company Profile

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a suscept...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 624 1100
Fax: 650 624 1101
Address:
611 Gateway Boulevard, Suite 900, South San Francisco, United States
GO_DAWGS
GO_DAWGS Aug. 31 at 9:18 AM
$RIGL FOST high on NIH's and BARD's radars (2 of 2) "When health is compromised by infection, insult, or injury, the body's response can trigger a cascade of immune dysregulation and organ dysfunction, leading to poor patient outcomes. Treatments aimed at modulating these responses, known as host-directed therapeutics (HDTs), have the potential to prevent, reduce or mitigate immediate and long-term harm through promoting a balance of healthy cells, tissue, immune system or organ function." https://drive.hhs.gov/host_tx.html (select list of partners)
0 · Reply
GO_DAWGS
GO_DAWGS Aug. 31 at 9:15 AM
$RIGL FOST high on NIH's and BARD's radars (1 of 2) "A team of IRP researchers discovered that Fostamatinib, an FDA-approved drug that inhibits an enzyme called spleen tyrosine kinase (SYK), can reduce the hyper-activity of immune cells called neutrophils that contribute to sepsis. The scientists found that Fostamatinib was able to inhibit three different functions of neutrophils that contribute to organ injury during sepsis when those cells are over-active. Importantly, the drug did not inhibit neutrophils’ other functions, including their ability to engulf and destroy bacteria and dead cells, known as phagocytosis." https://irp.nih.gov/accomplishments/discovering-a-potential-treatment-for-sepsis
0 · Reply
MaxKlim
MaxKlim Aug. 31 at 8:06 AM
0 · Reply
Gabriel1234
Gabriel1234 Aug. 31 at 7:37 AM
$RIGL Conclusion: The conferences are aimed at large and influential investors, not small retail investors. Participation gives Rigel the opportunity to build confidence with parties that can significantly impact the stock price and future financing.
0 · Reply
Gabriel1234
Gabriel1234 Aug. 31 at 7:36 AM
$RIGL Hedge funds and private equity These funds actively seek high-growth biotech companies with potential blockbuster drugs. They often have substantial capital reserves and can take significant equity positions. Other large institutional investors Pension funds, endowment funds, and mutual funds specialized in biotech and healthcare.
0 · Reply
Gabriel1234
Gabriel1234 Aug. 31 at 7:36 AM
$RIGL investor conferences Rigel Pharmaceuticals is participating in typically attract large institutional investors, such as: Investment banks and asset managers For example, Citi and Wells Fargo, which each manage large client portfolios. These banks organize the conferences and bring together their top clients (institutional investors, hedge funds, pension funds) with biotech companies.
0 · Reply
Gabriel1234
Gabriel1234 Aug. 31 at 7:34 AM
$RIGL https://www.gurufocus.com/news/3079155/rigel-to-participate-in-upcoming-september-investor-conferences-rigl-stock-news
0 · Reply
Gabriel1234
Gabriel1234 Aug. 31 at 7:33 AM
$RIGL Year 2026Low Scenario (5%)Mid Scenario Low (10%) 2026 $1.61B Mid$3.22B High Scenario (15%) $4.83B
0 · Reply
Gabriel1234
Gabriel1234 Aug. 31 at 7:29 AM
$RIGL Step 3: Cumulative Royalties (2026–2030) ScenarioTotal 5-Year RoyaltiesLow (5%)$8.14BMid (10%)$19.26BHigh (15%)$27.40B
0 · Reply
Gabriel1234
Gabriel1234 Aug. 31 at 7:26 AM
$RIGL ScenarioAnnual market (2025–2030)Rigel's royalty (5–15%)Low$30.2 billion$1.51 billion – $4.53 billionMedium$35.6 billion$1.78 billion – $5.34 billionHigh$41.1 billion$2.06 billion – $6.17 billion
0 · Reply
Latest News on RIGL
Overlooked Stock: RIGL Nearly Doubles Stock in August

Aug 15, 2025, 5:20 PM EDT - 15 days ago

Overlooked Stock: RIGL Nearly Doubles Stock in August


The Big 3: OPEN, RIGL, JOBY

Aug 15, 2025, 12:00 PM EDT - 15 days ago

The Big 3: OPEN, RIGL, JOBY

JOBY OPEN


Rigel Pharmaceuticals: Q2 Earnings Fuel A Potential Breakout

Aug 13, 2025, 11:58 PM EDT - 17 days ago

Rigel Pharmaceuticals: Q2 Earnings Fuel A Potential Breakout


Rigel to Present at the Jefferies Global Healthcare Conference

May 28, 2025, 8:05 AM EDT - 3 months ago

Rigel to Present at the Jefferies Global Healthcare Conference


Rigel Pharmaceuticals: Q1 Earnings Showcase Growing Momentum

May 7, 2025, 6:16 PM EDT - 4 months ago

Rigel Pharmaceuticals: Q1 Earnings Showcase Growing Momentum


Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability

Apr 4, 2025, 3:31 PM EDT - 5 months ago

Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability


Rigel Appoints Mark W. Frohlich, M.D.

Mar 10, 2025, 8:05 AM EDT - 6 months ago

Rigel Appoints Mark W. Frohlich, M.D.


Rigel Provides Business Update and 2025 Outlook

Jan 13, 2025, 8:05 AM EST - 8 months ago

Rigel Provides Business Update and 2025 Outlook


Rigel to Present at the Jefferies London Healthcare Conference

Nov 12, 2024, 8:05 AM EST - 10 months ago

Rigel to Present at the Jefferies London Healthcare Conference


Rigel Pharmaceuticals: Looking For More Growth

Oct 10, 2024, 7:32 AM EDT - 11 months ago

Rigel Pharmaceuticals: Looking For More Growth


Rigel Announces Reverse Stock Split

Jun 25, 2024, 8:00 AM EDT - 1 year ago

Rigel Announces Reverse Stock Split


GO_DAWGS
GO_DAWGS Aug. 31 at 9:18 AM
$RIGL FOST high on NIH's and BARD's radars (2 of 2) "When health is compromised by infection, insult, or injury, the body's response can trigger a cascade of immune dysregulation and organ dysfunction, leading to poor patient outcomes. Treatments aimed at modulating these responses, known as host-directed therapeutics (HDTs), have the potential to prevent, reduce or mitigate immediate and long-term harm through promoting a balance of healthy cells, tissue, immune system or organ function." https://drive.hhs.gov/host_tx.html (select list of partners)
0 · Reply
GO_DAWGS
GO_DAWGS Aug. 31 at 9:15 AM
$RIGL FOST high on NIH's and BARD's radars (1 of 2) "A team of IRP researchers discovered that Fostamatinib, an FDA-approved drug that inhibits an enzyme called spleen tyrosine kinase (SYK), can reduce the hyper-activity of immune cells called neutrophils that contribute to sepsis. The scientists found that Fostamatinib was able to inhibit three different functions of neutrophils that contribute to organ injury during sepsis when those cells are over-active. Importantly, the drug did not inhibit neutrophils’ other functions, including their ability to engulf and destroy bacteria and dead cells, known as phagocytosis." https://irp.nih.gov/accomplishments/discovering-a-potential-treatment-for-sepsis
0 · Reply
MaxKlim
MaxKlim Aug. 31 at 8:06 AM
0 · Reply
Gabriel1234
Gabriel1234 Aug. 31 at 7:37 AM
$RIGL Conclusion: The conferences are aimed at large and influential investors, not small retail investors. Participation gives Rigel the opportunity to build confidence with parties that can significantly impact the stock price and future financing.
0 · Reply
Gabriel1234
Gabriel1234 Aug. 31 at 7:36 AM
$RIGL Hedge funds and private equity These funds actively seek high-growth biotech companies with potential blockbuster drugs. They often have substantial capital reserves and can take significant equity positions. Other large institutional investors Pension funds, endowment funds, and mutual funds specialized in biotech and healthcare.
0 · Reply
Gabriel1234
Gabriel1234 Aug. 31 at 7:36 AM
$RIGL investor conferences Rigel Pharmaceuticals is participating in typically attract large institutional investors, such as: Investment banks and asset managers For example, Citi and Wells Fargo, which each manage large client portfolios. These banks organize the conferences and bring together their top clients (institutional investors, hedge funds, pension funds) with biotech companies.
0 · Reply
Gabriel1234
Gabriel1234 Aug. 31 at 7:34 AM
$RIGL https://www.gurufocus.com/news/3079155/rigel-to-participate-in-upcoming-september-investor-conferences-rigl-stock-news
0 · Reply
Gabriel1234
Gabriel1234 Aug. 31 at 7:33 AM
$RIGL Year 2026Low Scenario (5%)Mid Scenario Low (10%) 2026 $1.61B Mid$3.22B High Scenario (15%) $4.83B
0 · Reply
Gabriel1234
Gabriel1234 Aug. 31 at 7:29 AM
$RIGL Step 3: Cumulative Royalties (2026–2030) ScenarioTotal 5-Year RoyaltiesLow (5%)$8.14BMid (10%)$19.26BHigh (15%)$27.40B
0 · Reply
Gabriel1234
Gabriel1234 Aug. 31 at 7:26 AM
$RIGL ScenarioAnnual market (2025–2030)Rigel's royalty (5–15%)Low$30.2 billion$1.51 billion – $4.53 billionMedium$35.6 billion$1.78 billion – $5.34 billionHigh$41.1 billion$2.06 billion – $6.17 billion
0 · Reply
Gabriel1234
Gabriel1234 Aug. 31 at 7:26 AM
$RIGL recent report by BCC Research, the global market for rheumatoid arthritis (RA) therapies was valued at $28.5 billion in 2024 and is expected to grow to $41.1 billion by 2030, with a compound annual growth rate (CAGR) of 6.3% from 2025 through 2030 (bccresearch.com).(bccresearch.com) If we combine these figures with the previously discussed royalty percentages (5–15%), we can estimate Rigel Pharmaceuticals' potential annual revenue from the collaboration with Eli Lilly for LY3871801 (ocadusertib)
0 · Reply
Gabriel1234
Gabriel1234 Aug. 31 at 7:24 AM
$RIGL https://www.bccresearch.com/market-research/pharmaceuticals/therapies-rheumatoid-arthritis-markets-report.html#:~:text=Report%20Highlights,6.3%25%20from%202025%20through%202030.
0 · Reply
Gabriel1234
Gabriel1234 Aug. 31 at 7:10 AM
$RIGL https://www.clinicaltrials.gov/study/NCT05848258?term=AREA%5BBasicSearch%5D(J3P-MC-FTAF)&rank=1
0 · Reply
Gabriel1234
Gabriel1234 Aug. 31 at 7:09 AM
$RIGL price can increase at least 7 times like Abivax. The big jump would come only if strong Phase 2 data is release. This news is positive for Rigel because it confirms that the program is progressing well and that Lilly has confidence in it. However, it is mainly a long-term catalyst: the real stock impact will depend on the clinical results.
0 · Reply
Gabriel1234
Gabriel1234 Aug. 31 at 7:02 AM
$RIGL Timing: the rheumatoid arthritis market is huge (USD 30–40 billion per year). If LY3871801 performs well, even a modest market share could generate billions in revenue, from which Rigel would get a percentage.
0 · Reply
Gabriel1234
Gabriel1234 Aug. 31 at 7:02 AM
$RIGL Partnership with Eli Lilly: Rigel does not have to invest billions itself; Lilly carries the heavy burden of development and marketing. Rigel mainly receives milestone payments and royalties, which is a relatively low-risk revenue model for a smaller biotech.
0 · Reply
Gabriel1234
Gabriel1234 Aug. 31 at 7:02 AM
$RIGL The program is moving forward: LY3871801 is now in a Phase 2a/2b study. This means that earlier safety signals and preclinical data were strong enough to continue. A cancellation or delay would have been negative, but the opposite is happening: the study is even expanding (for example, in India). https://www.tipranks.com/news/company-announcements/eli-lilly-and-rigel-pharmaceuticals-advance-rheumatoid-arthritis-study-with-ly3871801
0 · Reply
Gabriel1234
Gabriel1234 Aug. 30 at 7:32 PM
$RIGL Abivax = hype/high expectations, large market, but high risks (Phase 3, no partner). Price 7x Rigel = “de-risked” due to the Eli Lilly deal, but therefore less explosive upside. Value lies mainly in takeover potential (Sanofi or Lilly). Aurinia = proven product (Lupkynis), growing revenue, often in the news as a takeover target (because Lupkynis is unique in lupus nephritis). So price Rigel Pharmaceuticals can bet also 4-5 times
0 · Reply
Gabriel1234
Gabriel1234 Aug. 30 at 7:21 PM
$RIGL Lilly could feel threatened and respond with its own counteroffer. This situation could lead to a bidding battle, which usually benefits Rigel’s investors.
0 · Reply
Gabriel1234
Gabriel1234 Aug. 30 at 7:20 PM
$RIGL What Sanofi would actually buy If Sanofi acquired Rigel, the existing collaboration with Lilly would carry over (unless specifically excluded in the contract). In that case, Sanofi would effectively step into Rigel’s role as Lilly’s partner on the RIPK1 project. Strategic tension Sanofi and Lilly are both big pharma companies and sometimes direct competitors (especially in immunology). Lilly might see this as a threat and could choose to:
1 · Reply
Gabriel1234
Gabriel1234 Aug. 30 at 7:20 PM
$RIGL Exclusive license to LY3871801 and possibly other RIPK1 programs. Right of first refusal / negotiation, meaning Lilly could have the first chance to make an offer if Rigel enters talks with another buyer. Collaboration protection, requiring any new owner (like Sanofi) to honor the existing deal.
0 · Reply
Gabriel1234
Gabriel1234 Aug. 30 at 7:19 PM
$RIGL A collaboration such as the one between Eli Lilly and Rigel Pharmaceuticals can often be a precursor to a full acquisition. This is something we often see in the pharmaceutical industry: If Sanofi wanted to acquire Rigel Pharmaceuticals while Eli Lilly already has a collaboration: Eli Lilly’s contractual rights Typically, Lilly’s collaboration agreement with Rigel would include certain protections, such as:
0 · Reply